explore -WSS

explore

author：leisure time 2025-10-03 00:38:06 - browse：981

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Roivant's CEO is a star, but biotech's black hole persists

entertainment

WSS

How AI can help patients find reliable information about doctors

Results on Novartis prostate cancer therapy could expand its use

Wellcome Trust names Røttingen as its new CEO

Akero's treatment for NASH falls short in cirrhosis study

The problems with dementia villages

What's changing in Medicare's open enrollment this year?

knowledge

explore

entertainment

How to save PrEP access — and even expand it

Takeaways from AdvaMed, the largest medical devices conference

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Summit: Ending the crisis of Black deaths in the U.S.

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Summit: How researchers deal with rejection

Medical leaders decry Supreme Court decision on affirmative action

Roivant's CEO is a star, but biotech's black hole persists

In Memoriam: Notable people who died in 2023

Nick Jonas talks about managing diabetes along with his career

leisure time

Massive project maps cells in human brain in unprecedented detail

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Results on Novartis prostate cancer therapy could expand its use

How AI can help patients find reliable information about doctors

Takeaways from AdvaMed, the largest medical devices conference

STAT Summit: The economic case for universal basic health care

explore

focus

entertainment

focus